Recruiting
Informing Implementation of a Circadian-Focused Intervention for Postpartum Depression
The proposed study is an open-label trial of Re-Timer® wearable morning bright light therapy for postpartum depression. The study is focused on evaluating the feasibility, acceptability, and implementation context of morning Bright Light Treatment (mBLT) for postpartum depression.
ClinicalTrials.gov IDNCT07766161
PhaseNA
Enrollment30
SponsorUniversity of Michigan
Age18 Years and older
SexFEMALE
Conditions studied
Postpartum Depression (PPD)
About this study
The proposed study is an open-label trial of Re-Timer® wearable morning bright light therapy for postpartum depression. The study is focused on evaluating the feasibility, acceptability, and implementation context of morning Bright Light Treatment (mBLT) for postpartum depression.
Interventions
- Device: Light therapy — Participants will use the Re-Timer daily for 5 weeks (approximately 35 days). All participants will be provided with a "light therapy window" during which they will wear the device for 60 mins.
Primary outcomes
- Retention rate (At approximately 5 weeks after treatment is started (post-treatment))
- Adherence rate (as assessed through self-report) (At approximately 5 weeks after treatment is started (post-treatment))
Eligibility information
Inclusion Criteria:
1. ≤ 6 months postpartum
2. EPDS score \>10
Exclusion Criteria:
1. Current or past-year substance use disorder
2. Lifetime history of bipolar disorder or psychotic disorder
3. Active suicidal intent
4. Retinal pathology or history of eye surgery
5. Current use of photosensitizing medications
6. Untreated sleep-disordered breathing, untreated restless legs syndrome, or narcolepsy
7. Psychotherapy or psychotropic medications started/dose changed in past month (psychotherapy started and/or current medication at stable dose ≥ 4 weeks are permitted)
8. Medical conditions contraindicated for mBLT (e.g., epilepsy/seizures)
Study locations
- University of Michigan, Ann Arbor, Michigan 48109 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-19.